652 related articles for article (PubMed ID: 4213265)
41. Resistance to gentamicin and amikacin of gram-negative organisms isolated from horses.
Orsini JA; Benson CE; Spencer PA; Van Miller E
Am J Vet Res; 1989 Jun; 50(6):923-5. PubMed ID: 2669575
[TBL] [Abstract][Full Text] [Related]
42. Susceptibility of aerobic gram-negative bacilli to aminoglycosides. Effects of 45 months of amikacin as first-line aminoglycoside therapy.
Saavedra S; Vera D; Ramírez-Ronda CH
Am J Med; 1986 Jun; 80(6B):65-70. PubMed ID: 3014877
[TBL] [Abstract][Full Text] [Related]
43. UK31214, a new aminoglycoside and derivative of kanamycin B.
Wise R; Andrews JM; Bedford KA
Antimicrob Agents Chemother; 1980 Mar; 17(3):298-301. PubMed ID: 6775590
[TBL] [Abstract][Full Text] [Related]
44. In vitro susceptibility of gentamicin-resistant Enterobacteriaceae and Pseudomonas aeruginosa to aminoglycoside antibiotics.
Ramírez-Ronda CH; Nevárez M; Gutiérrez-Núñez JJ; Reyes Y
Bol Asoc Med P R; 1983 Jul; 75(7):305-7. PubMed ID: 6442865
[No Abstract] [Full Text] [Related]
45. Analysis of neomycin, kanamycin, tobramycin and amikacin resistance mechanisms in gentamicin-resistant isolates of Enterobacteriaceae.
Adwan K; Abu-Hasan N; Al-Asmar H
J Med Microbiol; 1998 Nov; 47(11):1019-21. PubMed ID: 9822302
[TBL] [Abstract][Full Text] [Related]
46. Comparative in vitro activity of netilmicin, amikacin, tobramycin and sisomicin against gentamicin highly-resistant enterobacteriaceae.
Tselentis J; Legakis NJ; Nicolas KJ; Melissinos K; Papavassiliou J
Chemotherapy; 1980; 26(6):409-17. PubMed ID: 7408554
[TBL] [Abstract][Full Text] [Related]
47. In vitro activity of netilmicin compared with gentamicin, tobramycin, amikacin, and kanamycin.
Eickhoff TC; Ehret JM
Antimicrob Agents Chemother; 1977 May; 11(5):791-6. PubMed ID: 879733
[TBL] [Abstract][Full Text] [Related]
48. [Comparative study of the effect of sisomicin and other aminoglycosides on the causative agents of surgical infection].
Navashin PS
Antibiotiki; 1982 Dec; 27(12):26-9. PubMed ID: 6819812
[TBL] [Abstract][Full Text] [Related]
49. [Current status of aminoglycoside resistance in hospital Enterobacteriaceae].
Ronco E; Migueres ML; Vacheron F; Guenounou M
Pathol Biol (Paris); 1988 May; 36(5):430-4. PubMed ID: 3043339
[TBL] [Abstract][Full Text] [Related]
50. The potential for discovery and development of improved aminoglycosides.
Price KE
Am J Med; 1986 Jun; 80(6B):182-9. PubMed ID: 3089002
[TBL] [Abstract][Full Text] [Related]
51. Transduction of amikacin, gentamicin and tobramycin resistance in Pseudomonas aeruginosa.
Knothe H; Krcméry V; Mitsuhashi S
Zentralbl Bakteriol A; 1980 Mar; 246(3):373-8. PubMed ID: 6775445
[TBL] [Abstract][Full Text] [Related]
52. In vitro comparison of kanamycin, kanendomycin, gentamicin, amikacin, sisomicin, and dibekacin against 200 strains of Pseudomonas aeruginosa.
Paradelis AG; Douboyas J; Stathopoulos G; Grigoriadou-Edipides A; Triantaphylidis C; Papapanagiotou J
Antimicrob Agents Chemother; 1978 Sep; 14(3):514-5. PubMed ID: 101135
[TBL] [Abstract][Full Text] [Related]
53. In vitro efficacy of Bay k 4999, a new ureido-penicillin, in combination with aminoglycosides against Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae and Proteus strains.
Daschner FD; Steffens A; Langmaack H
Chemotherapy; 1979; 25(5):282-5. PubMed ID: 113178
[TBL] [Abstract][Full Text] [Related]
54. Aminoglycoside resistance in gram-negative bacilli during increased amikacin use. Comparison of experience in 14 United States hospitals with experience in the Minneapolis Veterans Administration Medical Center.
Gerding DN; Larson TA
Am J Med; 1985 Jul; 79(1A):1-7. PubMed ID: 4025364
[TBL] [Abstract][Full Text] [Related]
55. [Dibekacin--a novel aminoglycoside antibioticl. Antimicrobial activity and parallel resistance in vitro].
Schassan HH; Witt U
Arzneimittelforschung; 1979; 29(2):174-8. PubMed ID: 582126
[TBL] [Abstract][Full Text] [Related]
56. Emergence in a burn center of populations of bacteria resistant to gentamicin, tobramycin, and amikacin: evidence for the need for changes in zone diameter interpretative standards.
Minshew BH; Pollock HM; Schoenknecht FD; Sherris JC
Antimicrob Agents Chemother; 1977 Dec; 12(6):688-96. PubMed ID: 412464
[TBL] [Abstract][Full Text] [Related]
57. Aminoglycoside resistance among blood culture isolates.
Huovinen P; Grönroos P; Herva E; Katila ML; Klossner ML; Renkonen OV; Toivanen P
J Clin Microbiol; 1984 Jul; 20(1):65-9. PubMed ID: 6378968
[TBL] [Abstract][Full Text] [Related]
58. Preclinical comparative evaluation of aminoglycosides.
Abbate GF; Alagia I; Giaquinto E; Giordano B; Leonessa V; Altucci P
Chemioterapia; 1984 Dec; 3(6):378-84. PubMed ID: 6529780
[TBL] [Abstract][Full Text] [Related]
59. In vitro susceptibility of clinically important bacteria to amikacin: correlation of results of broth dilution and disk sensitivity tests and effect of medium composition.
Linzenmeier G; Naumann P; Neussel H; Rosin H
J Infect Dis; 1976 Nov; 134 SUPPL():S262-70. PubMed ID: 825584
[TBL] [Abstract][Full Text] [Related]
60. Sisomicin: evaluation in vitro and comparison with gentamicin and tobramycin.
Crowe CC; Sanders E
Antimicrob Agents Chemother; 1973 Jan; 3(1):24-8. PubMed ID: 4790572
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
